Skip to main content

Search Videos and More

Showing 73 - 84 of 162 results

Previous| 1... 6 | 7 | 8 ...14 |Next

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue?

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

Based on the ODYSSEY Outcomes and FOURIER Trials, which patient populations, including individuals with T2D, do you believe should be targeted for PCSK9 inhibitors?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

What percentage of patients have statin muscle intolerance based on the criteria you and your colleagues have developed? Why is there a disconnect between the prevalence of statin muscle intolerance vs the results reported in major trials?

What percentage of patients have statin muscle intolerance based on the criteria you and your colleagues have developed? Why is there a disconnect between the prevalence of statin muscle intolerance vs the results reported in major trials?

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy?

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy?

How have recent PCSK9 trials affected your position on the role of intensifying LDL-C reductions to new target levels, and how are they likely to affect future global/ESC 2019 guidelines for LDL-mediated CV risk reduction?

How have recent PCSK9 trials affected your position on the role of intensifying LDL-C reductions to new target levels, and how are they likely to affect future global/ESC 2019 guidelines for LDL-mediated CV risk reduction?

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

What change in practice, based on the all-cause mortality reduction reported in ODYSSEY Outcomes, do you believe is warranted, especially as these results might impact the LDL-C level that should be targeted and the duration of therapy?

Showing 73 - 84 of 162 results

Previous| 1... 6 | 7 | 8 ...14 |Next